BRD2 and neuroblastoma: The results indicated that, in comparison with the low-risk group, the mRNA expression levels of AKR1C1, BCAT2, HNRNPA2B1, ATG3, AKT1S1, CYGB, and FADS2 were significantly elevated in the high-risk group of NB; the mRNA expression levels of IFNA10, IFNA21, CDO1, ATF2, and ATG16L were significantly decreased in the high-risk group of NB; there were no statistically significant differences in the expression levels of BRD2, HDDC3, DAZAP1, FTH1, BRD4, DHODH, and HSF1 between the two groups of NB (Supplementary Fig. 1).